Valuation: MacroGenics, Inc.

Market Cap 286M 250M 231M 213M 402M 27.47B 409M 2.76B 1.08B 13.45B 1.07B 1.05B 46.32B P/E 2026 *
-6.71x
P/E 2027 * -2.95x
Enterprise Value 286M 250M 231M 213M 402M 27.47B 409M 2.76B 1.08B 13.45B 1.07B 1.05B 46.32B EV / Sales 2026 *
1.74x
EV / Sales 2027 * 3.03x
Free-Float
96.57%
Yield 2026 *
-
Yield 2027 * -
1 day-2.33%
1 week-7.68%
Current month-5.09%
1 month+6.17%
3 months+25.64%
6 months+146.35%
Current year+172.36%
1 week 4.16
Extreme 4.155
4.78
1 month 3.84
Extreme 3.845
5.08
Current year 1.58
Extreme 1.58
5.08
1 year 1.29
Extreme 1.29
5.08
3 years 0.99
Extreme 0.9897
21.88
5 years 0.99
Extreme 0.9897
28.09
10 years 0.99
Extreme 0.9897
36.48
Manager TitleAgeSince
Chief Executive Officer 53 13/08/2025
Director of Finance/CFO 59 01/05/2008
Chief Tech/Sci/R&D Officer 61 -
Director TitleAgeSince
Director/Board Member 73 01/09/2001
Director/Board Member 53 13/08/2025
Director/Board Member 62 01/10/2004
Date Insider Type Main position Quantity % Market Cap.
05-19Free

Founder

25,750 0.0405%
05-19Free

Director

25,750 0.0405%
05-19Free

Director

25,750 0.0405%
Change 5-day change 1-year change 3-year change Capi.($)
-2.33%-7.68%+177.53%-10.87% 286M
+6.05%+3.69%+65.28%+89.94% 53.54B
+0.21%-6.28%+56.18%+127.90% 54.18B
+0.60%-2.65%+7.81%+433.25% 23.66B
+0.73%-3.74%-18.23%-16.15% 22.78B
+2.36%+1.06%+43.34%-6.14% 19.54B
-2.29%-1.92%+35.57%-29.14% 17.82B
-4.00%-7.88%+175.60%+343.60% 16.01B
-1.15%-4.83%+46.53%+627.30% 15.37B
-0.67%-2.51%+22.08%+186.98% 14.09B
Average -0.04%-1.47%+61.17%+174.67% 23.73B
Weighted average by Cap. +1.18%-0.46%+49.22%+163.37%

Financials

2026 *2027 *
Net sales 164M 144M 133M 123M 231M 15.79B 235M 1.58B 621M 7.73B 617M 604M 26.62B 94.26M 82.37M 76.15M 70.35M 132M 9.05B 135M 908M 356M 4.43B 354M 346M 15.27B
Net income -18.31M -16M -14.79M -13.66M -25.73M -1.76B -26.19M -176M -69.19M -861M -68.76M -67.24M -2.96B -127M -111M -103M -94.82M -179M -12.2B -182M -1.22B -480M -5.98B -477M -467M -20.57B
Net Debt - -
Logo MacroGenics, Inc.
MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.
Employees
293
Date Price Change Volume
15/07/26 US$4.380 -2.67% 940,124
13/07/26 US$4.500 +3.93% 1,124,151
10/07/26 US$4.330 -5.25% 744,697
09/07/26 US$4.570 -1.93% 691,944
08/07/26 US$4.660 -1.89% 701,220
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
4.500USD
Average target price
6.750USD
Spread / Average Target
+50.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MGNX Stock